News Release

<< Back

Sunesis Pharmaceuticals Hosts Conference Call to Discuss Preliminary SNS-595 Activity in its Ovarian Cancer Clinical Trial Being Reported at the AACR-NCI-EORTC International Conference

10/23/07

SOUTH SAN FRANCISCO, Calif., Oct 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), today announced that management will host a conference call this afternoon at 3:30 p.m. Eastern Time/12:30 p.m. Pacific Time to review preliminary data from Sunesis' ongoing Phase 2 clinical trial of SNS-595 in platinum-resistant ovarian cancer. Joining management on the call will be a clinical investigator participating in the current clinical trial.

Preliminary data from the Phase 2 clinical trial are being presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Abstract #A158, a poster titled "A Phase 2 trial of SNS-595 in women with platinum refractory epithelial ovarian cancer." The poster will be on view as part of Poster Session A -- Clinical Trials in the Moscone Convention Center West Exhibit Hall and will also be available on the Sunesis corporate website at http://www.sunesis.com.

Individual and institutional investors can access the call via (877) 681-3375 (U.S. and Canada) or (719) 325-4888 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media -- Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SOURCE Sunesis Pharmaceuticals, Inc.

http://www.sunesis.com

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX